Peptide LibraryVesugen
Also known as: Lys-Glu-Asp, Vascular bioregulator
Vesugen (also called Lys-Glu-Asp or Vascular bioregulator) is a khavinson vascular tripeptide in the Short Peptide Bioregulator class. Vesugen is Lys-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with vascular tissue.
For research use only.
Key Facts
- CAS
- 204271-66-9
- Molecular Weight (MW)
- ≈390.4 g/mol
- Half-life
- Not established (limited public PK data; primarily research context)
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Vascular endothelium (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 6
- Listed offers
- 7
- Median price per mg
- $3.00/mg
- Typical $2.81–$3.62/mg
Research summary
Lys-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series associated with vascular tissue and endothelial function. It is distinct from Ventfort, the tissue extract marketed for the same purpose. The proposed activity rests on cell-culture and cytogenetic work from one research group published mainly in Russian, without independent replication or controlled human evidence. Not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studies4 reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Vesugen profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Vesugen dosage: no established human dose
Vesugen has no established human dosage. It is the synthetic tripeptide Lys-Glu-Asp (KED) from the Khavinson bioregulator series. No trial of it is registered on ClinicalTrials.gov. Four small Russian human reports are indexed, one on erectile dysfunction with vesugen alone and three with pinealon as well, and none of their abstracts states the dose or route.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Vesugen (Lys-Glu-Asp) is a short synthetic peptide from the Russian bioregulator research school. Its literature is mostly cell work on vascular, skin and nerve cells, plus a few small Russian human reports. None of the indexed human abstracts gives a dose, route or course length, and no study is registered internationally, so no human dose can be stated from verifiable sources.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not stated in the indexed human studies |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-11-07 |
Human research reported
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Vasculogenic erectile dysfunction, vesugen alone (2014)Clinical trial · Uncontrolled before-and-after clinical report, Russian-language publication | Patients with vasculogenic erectile dysfunction linked to atherosclerosis (n=41) | Not stated in the indexed abstract | Not stated in the indexed abstract | — | — | Better blood flow in the main penile arteries after treatment, by clinical and instrument measures | [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people]. Adv Gerontol. 2014. |
| Biological-age markers with vesugen or pinealon (2015)Clinical trial · Clinical study, Russian-language publication | Adults aged 41–83 with several chronic illnesses and organic brain syndrome in remission (n=32) | Not stated in the indexed abstract | Not stated in the indexed abstract | — | — | The authors report slower biological ageing by their markers, stronger with vesugen; a fall in blood CD34+ cells and a pro-oxidant effect were also seen | [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission]. Adv Gerontol. 2015. |
| Comparison of geroprotective methods, including vesugen with pinealon (2016)Clinical trial · Comparative clinical study, Russian-language publication | Patients of different ages (n=110 across all methods) | Not stated in the indexed abstract | Not stated in the indexed abstract | — | — | The largest change in biological-age markers was reported for vesugen and pinealon combined | [Comparative analysis of different methods of geroprotective]. Adv Gerontol. 2016. |
| Occupational study in professional truck drivers (2012)Clinical trial · Observational clinical report, Russian-language publication | Male truck drivers, with metal craftsmen as a comparison group (n=300) | Not stated in the indexed record | Not stated in the indexed record | — | — | Psychoemotional and stress-resistance measures; the best effect was reported for pinealon combined with vesugen | The peptide correction of neurotic disorders among professional truck-drivers. Adv Gerontol. 2012. |
Where sources disagree
- Daily protocols for vesugen are widely published. No registered trial or indexed human study reports a dose for it.
- In three of the four human reports, vesugen was given with pinealon, so effects cannot be attributed to vesugen alone.
- The 2014 erectile-dysfunction report is titled as a study of lower-limb arterial disease, but its abstract describes erectile dysfunction in 41 patients.
- Vesugen (a synthetic tripeptide) and Ventfort (a vascular tissue extract sold as capsules) are different products.
Reconstitution
Common research vial sizes: 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 20 mg | 2 mL | 10 mg/mL | 100 mcg per 0.01 mL |
| 20 mg | 4 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- If lyophilized: reconstitute with bacteriostatic water per lab SOP (research only)
- Injection Sites
- Abdomen (subQ)
- Concentration Example
- 20 mg vial reconstituted with 2 mL = 10 mg/mL
- Timing Notes
- Often administered in the morning; consistency is emphasized in bioregulator protocols
- Expected Onset
- Variable; proposed cellular signaling effects over weeks
Sequence & molecular data
| Amino acid sequence | Lys Glu Asp (KED) |
|---|---|
| Molecular formula | C15H26N4O8 |
| Molecular weight | ≈390.4 g/mol |
| CAS number | 204271-66-9 |
| Half-life | Not established (limited public PK data; primarily research context) |
| Appearance | White lyophilized powder or tablets (supplier dependent) |
| Formulation | Lyophilized Powder |
| PubChem CID | 87571363 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Vesugen is Lys-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with vascular tissue. The series hypothesis proposes that such peptides enter the nucleus and interact with specific promoter sequences to influence transcription of tissue-relevant genes, with reported effects here on endothelial cell protein synthesis and vascular wall markers. The evidence consists of cell-culture and cytogenetic studies from one research group published mainly in Russian; there is no independent replication, no characterised receptor, and no modern randomised controlled trial evidence for vascular outcomes.
Origin
Synthetic short peptide.
Targets
Studies
- [Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.]
- Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells
- Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease
- [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people]
Research statistics
7 PubMed publications · 14.3% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Vesugen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Vesugen side effects
Vesugen has only limited human data, so the list below is incomplete and its side-effect profile is not well established.
Side Effects
- Not characterized
Stacking
Common stacking partners
Combinations that include Vesugen, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Vesugen: frequently asked questions
What is Vesugen?
Lys-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series associated with vascular tissue and endothelial function. It is distinct from Ventfort, the tissue extract marketed for the same purpose. The proposed activity rests on cell-culture and cytogenetic work from one research group published mainly in Russian, without independent replication or controlled human evidence. Not FDA-approved.
How does Vesugen work?
Vesugen is Lys-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with vascular tissue. The series hypothesis proposes that such peptides enter the nucleus and interact with specific promoter sequences to influence transcription of tissue-relevant genes, with reported effects here on endothelial cell protein synthesis and vascular wall markers.
Is Vesugen FDA approved?
No. Vesugen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Vesugen?
Reported half-life for Vesugen is Not established (limited public PK data; primarily research context). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Vesugen?
Vesugen has the sequence Lys Glu Asp (KED). Its molecular formula is C15H26N4O8.
What peptides are similar to Vesugen?
Compounds most often compared with Vesugen include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.] — Adv Gerontol, 2024External reference
- Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells — Bull Exp Biol Med, 2012External reference
- Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease — Bull Exp Biol Med, 2021External reference
- [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people] — Adv Gerontol, 2014External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4
This Vesugen profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Vesugen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →